SmallCapFirm

ODYY Update: Check Out The Huge Volume Surge On Today's Healthcare Profile

July 10th

SCF Members,

ODDY is trading in the green today on a major early morning volume surge.

According to Barchart, ODYY had traded over 2X its YTD daily average of shares traded (53K+) by 9:50AM EST (118K+).

Remember, ODYY previously moved 46% in the short-term after the first time I brought it to your attention.

Could we see another short-term breakout once again?

If you haven't read my full ODYY report, do so below and get it on your radar now.

-----

On June 17th after the market closed, I asked you to get Odyssey Group International, Inc. (ODYY) on your radar after the stock closed that day at $.75.

Here's what it did next:

That white line represents a move from June 17th's close of $.75 to a high of $1.10 on June 30th, less than 2 weeks later.

Overall, that surge resulted in an approximate 46% run in the short-term.

Now, with ODYY trading around those same June 17th levels again, it could be lining up for a return to those previous highs or beyond if/when they receive FDA approval.

Now, history has shown time and time again that FDA approval is exactly what a company needs to almost ensure its shares go vertical.

Examples exist of healthcare companies that, because of funding constraints, only work on one or two major devices/treatments at any specific time. As soon as those companies land FDA approvals, their shares have been known to surge as markets pay close attention to this type of game-changing news.

When it comes to regulatory bodies that affect a healthcare company's share price, none exceed the importance of the U.S. Food and Drug Administration (FDA).

If a company's device becomes FDA approved then they can begin selling their new product. Selling makes money; more revenue can lead to increased stock prices.

Small healthcare stocks are known for making heroic moves, often when their development-phase drugs or devices move closer to going commercial.

With each year, a significant proportion of U.S. society is diagnosed with diverse forms of heart disease.

Odyssey Group International’s initial product technology, CardioMap®, could be ready to swallow up that market due to its unparalleled tech and transportable design.

CardioMap® is intended to provide early, non-invasive testing of heart disease. With its highly portable design and web-based analysis, it can both penetrate the existing $28B cardiac device market and also expand the market vertical by opening up the possibilities for remote and home screening.

CardioMap will depict disease or stress levels, along with current heart conditions as a 3D image supplementing the line drawing electrocardiogram (ECG), but with device sensitivity that surpasses standard ECG analyzers. It is highly portable and provides a rapid analysis in less than 60 seconds.

In addition, when FDA approved, the CardioMap could be the only device in the world that has a predictive value. All other methods presently used, including ECG, Stress Tests, EHO, etc., either define patients as 'healthy' (no pathology, no changes) or 'sick '(there is a pathology and/or organic changes).

The CardioMap could be the only device that has the ability to show the ‘grey’ areas where deterioration has begun but not lead to pathology yet. This will be a phenomenal incentive for doctors to use the CardioMap device.

-----

ODYY Is Not Into Hearts Only, They Are Looking To Improve Brain Health Also!

Last year, ODYY and Prevacus Inc. entered into a Master Agreement to form a joint venture.

Prevacus is a drug development company working on the prevention and treatment of mild traumatic brain injury (mTBI) or concussion.

Prevacus' first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.

At this moment, no drugs are able to treat concussions.

With the partnership between Odyssey and Prevacus, the first ever treatment for concussions could be on the horizon.

Wouldn't that be an unreal achievement that could plaster ODYY across Wall Street's radar? Just imagine...

Right now, the nasal spray is currently in the early stages of testing.

-----

Your No. 1 ODYY Potential Catalyst For Vertical Growth

When you see a stock get equity financing, the strike price is usually well below the current stock price. Why? Because whoever lent money to the company has to profit when they eventually sell the stock.

They want a built in buffer. Get this...

Vivakor, Inc. who is an existing lender to the company, just lent more money to the company convertible at $1.00/share.

The current price is approximately $.697/share (at close Thursday). That means they believe this stock is worth much more than the current levels. Read on:

Odyssey Group International Strengthens Balance Sheet

Existing Note Holder Agrees to Convert to Equity at $1.00 per Share

IRVINE, CA / ACCESSWIRE / June 9, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that Vivakor, Inc. and existing note holder, has agreed and executed documents to convert the balance of its convertible note in the amount of $805K+ into equity of Odyssey. The agreed upon conversion is a price of $1.00 per common share.

Vivakor's Chief Executive Officer, Matt Nicosia, stated, "We are pleased with the progress Odyssey has made to date in developing its promising life saving medical products and we have full confidence in the team built at Odyssey. They continue to work with their partners to ready products for FDA submission with an eye on commercialization and we believe in their long term commercial success. Our confidence in Odyssey's CEO Michael Redmond is demonstrated by our willingness to convert to equity now at a fixed price of $1.00 per common share."

Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "We appreciate the backing and investment Vivakor has made in Odyssey over the years and Matt's support in helping us get to this stage. Their conversion into equity at $1.00 per common share is significant, as it eliminates over $800K of debt and strengthens our balance sheet."

-----

Your No. 2 ODYY Potential Catalyst For Vertical Growth

Odyssey Group International Provides Update on the Development of its Save a Life Choking Rescue Device

Plans to File for Additional Patents Around Unique Designs

IRVINE, CA / ACCESSWIRE / May 14, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to provide an update on the development of its Save a Life choking rescue device.

Product development and design partner Tanaka Kapec Design Group (TKDG) has made progress in its development effort with the ultimate goal of filing a submission to the FDA for the life-saving choking rescue device.

TKDG has accomplished phase one design tasks and built a working proof of principle model for testing repeatable performance and efficacy in a life-like anatomical model. This mechanical device has demonstrated its ability to extract a variety of lodged food samples from confined areas in the airway passage that typically cause asphyxiation.

TKDG has tested a working embodiment that falls within its patented technology.

Of note, Odyssey plans on filing additional patents on a new complementary probe design, which improves the process of safely removing a lodged food mass that would otherwise prevent breathing.

TKDG, with over 40 years of extensive experience and expertise in the medical industry, is providing strategic product development and industrial design to Odyssey's Save a Life choking rescue device.

-----

Your No. 3 ODYY Potential Catalyst For Vertical Growth

Odyssey Group International Signs Agreement with Majic LLC

Medical Device Engineering Firm to Assist with Development of CardioMap and Save a Life Choking Rescue Device

IRVINE, CA / ACCESSWIRE / March 2, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced today announced it has signed an agreement with Majic LLC, based in Salem, New Hampshire.

Majic, specializes in Systems Engineering, of medical devices, which encompasses integrating software, hardware, regulatory and manufacturing to insure consistent quality in high volume production.

Majic will implement its Systems Engineering approach to assist Odyssey on both CardioMap and Save a Life choking rescue device, and to ensure the products are integrated properly and address all regulatory requirements.

Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "Adding Majic to our partnership team, along with the previously announced Agreement with Tanaka Kapec Design Group, provides us with more experienced personnel who have successfully navigated medical devices from design and development through the 510k FDA process and commercialization. We believe we have assembled a strong team that will most efficiently and expeditiously transition our products to the next phase and closer to realizing their revenue potential. Additionally, we are seeking additional patent protection for both CardioMap and Save a Life choking rescue device."

CardioMap technology will be incorporated into a mobile device that will be specially designed for both individuals and medical professionals. Mobile health solutions and remote monitoring services are connecting physicians and patients. Odyssey is developing a technology that allows you to track the health of your heart anytime, anywhere. It is a unique ECG analysis algorithm and Internet service that makes prompt (as fast as 30 seconds) and extensive analysis of a person's heart health conditions. This analysis is achieved through an examination that measures heart performance and generates visual results as a dynamic, 3D colorful heart portrait.

Save a Life choking rescue device uses a patented "Negative Pressure" design to dislodge objects from the throat. It is an instantaneous, one step action that anyone can operate. It has been lab tested for proof of concept and addresses a large market application.

-----

Your No. 4 ODYY Potential Catalyst For Vertical Growth

Also, according to the OTC Markets' website, ODYY has a relatively small float.

In fact, there is only a reported 16Mn+ shares in its float.

With this amount of shares available for trading, there can be the potential for volatility if a catalyst brings in buzz to a profile like this.

Could the next big piece of news out of the ODYY camp be the thing to set this stock off on a vertical surge?

-----

Coverage officially initiated on ODYY immediately.

-----

If there are any other updates today, I'll have them out to you as quickly as possible.

Sincerely,

Axel Adams

Editor, SCF

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)​